

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in this Application:

1-32. (Canceled).

33. (Currently amended) A method for treatment of a vascular disease or states of tissue hypoperfusion, said disease or states of tissue hypoperfusion leading to hypoxia or ischemia in a patient, with the proviso that said method does not pertain to coronary ischemia, the method comprising the following steps:

administering a therapeutically effective amount of human apo-lactoferrin to the patient.

34. (Previously presented) The method as recited in claim 33 whereby the method is used for treating impending stroke, manifested stroke, and peripheral artery occlusive disease.

35. (Previously presented) The method as recited in claim 33 whereby the method is used for treating vascular disease, state of tissue hypoperfusion, or state of depressed VEGF induced angiogenesis associated with peptic ulcer, leg ulcer or local or generalised hair loss.

36. (Currently amended) The method as recited in claim 33 wherein said human apo-lactoferrin~~substance~~ is administered orally.

37. (Currently amended) The method as recited in claim 33 wherein said human apo-lactoferrin~~substance~~ is administered parenterally.

38. (Currently amended) The method as recited in claim 33 wherein said human apo-lactoferrin~~substance~~ is administered locally.

39. (Currently amended) The method as recited in claim 33 wherein said human apo-lactoferrin~~substance~~ is administered by inhalation.

40. (Currently amended) A method for treatment of a vascular disease or states of tissue hypoperfusion, said disease or states of tissue hypoperfusion leading to hypoxia or ischemia in a patient, with the proviso that said method does not pertain to coronary ischemia, the method comprising the following steps:

selecting a substance from ~~the group consisting of human apo-lactoferrin, and human lactoferricin, and a peptide having an amino acid sequence constituted of amino acids 12-40 of human lactoferrin counted from the N terminal end or a smaller fragment thereof which is at least 7 amino acids long, and optionally wherein said peptide is modified such that C-20 is replaced by A, Q-22 is replaced by K, and N-26 is replaced by D,~~ wherein said peptide substance is active in stimulating VEGF-mediated angiogenesis;

determining a therapeutically effective amount of the selected substance; and

administering the therapeutically effective amount of the selected substance to the patient.

41-46. (Canceled).

47. (Previously presented) The method as recited in claim 40 whereby the method is used for treating impending stroke, manifested stroke, and peripheral artery occlusive disease.

48. (Previously presented) The method as recited in claim 40 whereby the method is used for treating vascular disease, state of tissue hypoperfusion, or state of depressed VEGF induced angiogenesis associated with peptic ulcer, leg ulcer or local or generalised hair loss.

49. (Previously presented) The method as recited in claim 40 wherein said substance is administered orally.

50. (Previously presented) The method as recited in claim 40 wherein said substance is administered parenterally.

51. (Previously presented) The method as recited in claim 40 wherein said substance is administered locally.

52. (Previously presented) The method as recited in claim 40 wherein said substance is administered by inhalation.

53. (Previously presented) The method as recited in claim 34 wherein the treatment is for peripheral artery occlusive disease wherein conventional treatment is surgery or therapeutic angiogenesis and said method is used as an alternative to said conventional treatment.

54. (New) A method for treatment of a vascular disease or states of tissue hypoperfusion, said disease or states of tissue hypoperfusion leading to hypoxia or ischemia in a patient, with the proviso that said method does not pertain to coronary ischemia, the method comprising administering a therapeutically effective amount of human lactoferricin to the patient.